Skip to content
    Guidelines & Consensus

    Perioperative ctDNA in Resectable Gastric and GEJ Adenocarcinoma

    Sagawa et alJournal of Gastrointestinal Cancer

    Recurrence remains a principal cause of treatment failure following curative-intent multimodal therapy for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Conventional tools—including clinicopathological staging, pathological response grading, standard serum tumor markers, and cross-sectional imaging—fail to completely detect molecular residual disease (MRD). Circulating tumor DNA (ctDNA) provides a minimally invasive approach to address these diagnostic gaps, functioning across perioperative risk stratification, neoadjuvant response tracking, postoperative MRD identification, and early detection of molecular recurrence ahead of radiographic relapse.
    Among perioperative time points, postoperative ctDNA positivity exhibits the most consistent and reproducible correlation with disease recurrence and survival outcomes. Longitudinal monitoring also reveals that dynamic shifts—such as early ctDNA clearance during neoadjuvant treatment, persistence following preoperative therapy, and residual ctDNA after surgical resection or adjuvant chemotherapy—reflect clinically distinct molecular states.
    Despite its prognostic strength, significant technical and biological challenges impede immediate clinical adoption. Key limitations include assay heterogeneity between tumor-informed and tumor-agnostic platforms, non-standardized sampling windows, confounding from clonal hematopoiesis, and limited negative predictive value driven by low DNA shedding in diffuse-type histology and peritoneal-predominant metastases. Drawing parallels from colorectal cancer trials, strong prognostic biomarker performance does not inherently translate into improved survival in randomized treatment escalation or de-escalation strategies. Consequently, ctDNA currently functions best as an adjunctive tool for risk stratification and trial enrollment rather than an autonomous driver of therapeutic changes outside prospective clinical trials.

    Key Takeaways

    • Postoperative circulating tumor DNA positivity demonstrates the most reproducible association with recurrence and overall survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.
    • Current evidence restricts circulating tumor DNA use to an adjunct for risk stratification and clinical trial enrollment, advising against routine treatment adaptation outside prospective trials due to limited negative predictive value, low shedding in peritoneal or diffuse disease, and an absence of randomized clinical utility data.
    Read the original sourceJournal of Gastrointestinal Cancer